

CURRICULUM VITAE**INFORMAZIONI PERSONALI**

Nome	Giuseppe Traversa
Data di nascita	24 dicembre 1956
Qualifica	
Amministrazione	AGENZIA ITALIANA DEL FARMACO – AIFA
Incarico attuale	Dirigente Area Strategia ed Economia del Farmaco
Numero telefonico dell'ufficio	
E-mail istituzionale	g.traversa@aifa.gov.it

TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE

Titolo di studio	1983 Università degli Studi di Torino Laurea in Medicina e Chirurgia
Altri titoli di studio e professionali	1986 Università degli Studi di Torino Diploma di Specializzazione in Igiene e Medicina Preventiva
Esperienze professionali	Dal 2000 a novembre 2005 e da giugno 2009 ad aprile 2020 Primo ricercatore, Centro Nazionale di Epidemiologia e Centro Nazionale di Ricerca e Valutazione preclinica e clinica dei Farmaci, Istituto Superiore di Sanità, Roma Da dicembre 2005 a maggio 2009 Dirigente Ufficio Ricerca e Sviluppo (in comando dall'ISS), AIFA
Altri incarichi principali	1986-1999 Contrattista (1986-1989) e Tecnico (1990-1999) del Laboratorio di Epidemiologia e Biostatistica, Istituto Superiore di Sanità, Roma Gennaio 2016 – Gennaio 2020 Componente del Comitato scientifico dell'ISS Luglio 2018 – Giugno 2019 Componente del Tavolo tecnico di lavoro sui farmaci e i dispositivi

	<p>medici (Ministero della salute)</p> <p>Febbraio 2018 – Luglio 2018 Componente del Comitato prezzi e rimborso dell’Aifa</p> <p>Dicembre 2012 – Luglio 2014 Componente del Consiglio di Amministrazione dell’Agenzia italiana del farmaco (AIFA)</p> <p>2010-2011 Membro dello Steering Group ENCePP (European Network of Centers for Pharmacoepidemiology and Pharmacovigilance), EMA</p> <p>2003-2005 Membro del PhVWP (Pharmacovigilance Working Party) ed esperto del CPMP (Committee for Proprietary Medicinal Products) dell’EMA (European Medicines Evaluation Agency)</p> <p>1999-2001 Membro della Commissione per i medicinali omeopatici</p> <p>1998 Membro della Sottocommissione farmacovigilanza all’interno della Commissione Unica del Farmaco</p> <p>1998 Membro del “Gruppo di coordinamento centrale per la sperimentazione del Multitrattamento Di Bella”, dell’Istituto Superiore di Sanità</p> <p>1995-2000 Membro della Commissione preposta all’elaborazione del Prontuario terapeutico ospedaliero regionale (Regione Lazio)</p>									
<p>Capacità linguistiche</p>	<table border="1"> <thead> <tr> <th></th> <th>Livello orale</th> <th>Livello scritto</th> </tr> </thead> <tbody> <tr> <td>Inglese</td> <td>Buono</td> <td>Buono</td> </tr> <tr> <td>Francese</td> <td>Sufficiente</td> <td>Limitato</td> </tr> </tbody> </table>		Livello orale	Livello scritto	Inglese	Buono	Buono	Francese	Sufficiente	Limitato
	Livello orale	Livello scritto								
Inglese	Buono	Buono								
Francese	Sufficiente	Limitato								
<p>Capacità nell’uso delle tecnologie</p>										
<p>Altro: Pubblicazioni</p>	<p>Pubblicazioni scientifiche su riviste internazionali:</p> <ol style="list-style-type: none"> 1. Trotta F, Mayer F, Barone-Adesi F, Esposito I, Punreddy R, Da Cas R, Traversa G, Perrone F, Martini N, Gyawali B, Addis A. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. <i>BMJ open</i> 2019;9:e033728. doi:10.1136/ bmjopen-2019-033728. 2. Spila-Alegiani S, Trotta F, Da Cas R, Rossi M, Venegoni M, Traversa G. Comparative effectiveness of two tiotropium formulations: a retrospective cohort study. <i>COPD</i> 2018;15:418-23. https://doi.org/10.1080/15412555.2018.1554032 3. Marciànò I, Ingrassiotta Y, Giorgianni F, Ientile V, Chinellato A, Tari DU, Gini R, Cannavò S, Pastorello M, Scondotto S, Cananzi P, Traversa G, 									

Trotta F, Belleudi V, Addis A and Trifirò G (2018) Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014. *Front. Endocrinol.* 9:95. doi: 10.3389/fendo.2018.00095

4. Stoppa G, D'Amore C, Conforti A, Traversa G, Venegoni M, Tagliatela M, Leone R, on behalf of the ESAVIEW Study Group. Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study. *BioDrugs* 2018. <https://doi.org/10.1007/s40259-018-0293-2>
5. Trotta F, Spila Alegiani S, Da Cas R, Rajevic M, Conti V, Venegoni M, Rossi M, Traversa G. Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study. *PLoS ONE* 2017;12(4): e0176276. <https://doi.org/10.1371/journal.pone.0176276>
6. Barbui C, Addis A, Amato L, Traversa G, Garattini S. Can systematic reviews contribute to regulatory decisions? *Eur J Clin Pharmacol* 2017;73:507-509. doi: 10.1007/s00228-016-2194-y
7. Festa V, Spila Alegiani S, Chiesara F, Moretti A, Bianchi M, Dezi A, Traversa G, Koch M. Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis. *Eur Rev Med Pharmacol Sci* 2017;21:1397-404.
8. Traversa G, Masiero L, Saggiocca L, Trotta F. Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases. *OJRD* 2016;11:36.
9. D'Amore C, Da Cas R, Rossi M, Traversa G. Switching between epoetins: a practice in support of biosimilar use. *BioDrugs* 2016;30:27-32.
10. Trotta F, Da Cas R, Rajevic M, Rossi M, Traversa G. Risk factors influencing the prescription of tiotropium Respimat formulation: a population based cohort study. *BMJ Open* 2015;5:e006619. doi:10.1136/bmjopen-2014-006619
11. D'Amore C, Trotta F, Da Cas R, Zocchetti C, Cocci A and Traversa G. Antihypertensive drug use during pregnancy: a population based study. *Ann Ist Super Sanità* 2015;51:236-243.
12. Trotta F, Da Cas R, Spila Alegiani S, Gramegna M, Venegoni M, Zocchetti C, Traversa G. Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study. *BMJ* 2014; 348 doi: <http://dx.doi.org/10.1136/bmj.g3361>.
13. Trotta F, Da Cas R, Maggini M, Rossi M, Traversa G. Generic substitution of antidiabetic drugs in the elderly does not affect adherence. *Ann Ist Super Sanità* 2014;50:333-340.
14. Menniti-Ippolito F, Da Cas R, Traversa G et al. Vaccine effectiveness against severe laboratory-confirmed influenza in children: Results of two consecutive seasons in Italy. *Vaccine* 2014;32:4466-70. doi: 10.1016/j.vaccine.2014.06.048.
15. Raucci U, Rossi R, Da Cas R, Rafaniello C, Mores N, Bersani G, Reale A, Pirozzi N, Menniti-Ippolito F, Traversa G, and Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Stevens-Johnson

Syndrome associated with drugs and vaccines in children: a case-control study. PLoS ONE 2013; 8(7): e68231. doi:10.1371/journal.pone.0068231.

16. Saggiocca L, De Masi S, Ferrigno L, Mele A, Traversa G. A pragmatic strategy for the review of clinical evidence. *J Eval Clin Pract* 2013;19:689–96. doi: 10.1111/jep.12020.
17. Kuhnert R, Spila Alegiani S, Scalia Tomba G, Traversa G, Venneman M, Hecker H. The association between multidose vaccinations and death: comparing case series methods when the first exposure changes the general risk of an event. *Statistical methods and applications* 2013;22:573-587.
18. Bianciotto M, Chiappini E, Raffaldi I, Gabiano C, Tovo PA, Sollai S, De Martino M, Mannelli F, Tipo V, Da Cas R, Traversa G, Menniti-Ippolito F, and the Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Drug use and upper gastrointestinal complications in children: a case-control study. *Arch Dis Child* 2013;98:218-221. doi:10.1136/archdischild-2012-302100.
19. Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study. *BMJ Open* 2011;2:e000167. doi:10.1136/bmjopen-2011-000167.
20. Traversa G, Spila-Alegiani S, Bianchi C, Ciofi degli Atti M, Frova L, Massari M, Raschetti R, Salmaso S, Scalia Tomba G and the Hera study group. Sudden Unexpected Deaths and Vaccinations during the First Two Years of Life in Italy: a Case Series Study. *PLoS ONE*, 2011 Jan 26;6(1):e16363.
21. Italian Medicines Agency (AIFA) Research & Development Working Group. Feasibility and challenges of independent research on drugs: the Italian Medicines Agency experience. *Eur J Clin Invest* 2010;40:69-86.
22. Traversa G, Saggiocca L, Liberati A, Martini N. The need to promote independent research on drugs. *Ann Oncol* 2010;21:2295. (lettera)
23. Venegoni M, Da Cas R, Menniti-Ippolito F, Traversa G. Effects of the European restrictive actions concerning nimesulide prescription: a simulation study on hepatopathies and gastrointestinal bleedings in Italy. *Ann Ist Super Sanita* 2010;46:153-157.
24. Tafuri G, Trotta F, Leufkens HGM, Martini N, Saggiocca L, Traversa G. reply to: Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children. *Eur J Clin Pharmacol* 2009;65:851–852. (lettera)
25. Tafuri G, Trotta F, Leufkens HGM, Martini N, Saggiocca L, Traversa G. Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease. *Eur J Clin Pharmacol* 2009;65:209-216.
26. Menniti Ippolito F, Traversa G, Da Cas R, Leone R, Caputi A. Niflumic acid and mucocutaneous reactions. *Pediatrics*. 2006;117:253-254. (lettera)
27. Menniti-Ippolito F, Traversa G, Da Cas R, Rossi R, Renna S, Barabino P,

Saggiomo G, Vetrano F, Saggiocca L. Extrapiramidal reactions in children treated with metoclopramide. *Ital J Pediatr* 2004;30:49-52.

28. Boccia D, Spila Alegiani S, Pantosti A, Moro ML, Traversa G. The geographic relationship between the use of antimicrobial drugs and the pattern of resistance for *Streptococcus pneumoniae* in Italy. *Eur J Clin Pharmacol* 2004;60:115-119.
29. Maggini M, Raschetti R, Traversa G, Bianchi C, Caffari B, Da Cas R, Panei P. The cerivastatin withdrawal crisis: a "post-mortem" analysis. *Health Policy* 2004;69:151-157.
30. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. *BMJ* 2003;327:18-22.
31. Jefferson T, Traversa G. Hepatitis B vaccination: risk benefit profile and the role of systematic reviews in the assessment of causality of adverse events following immunisation. *J Med Virol* 2002;67:451-453.
32. Menniti-Ippolito F, Forcella E, Bologna E, Gargiulo L, Traversa G, Raschetti R. Use of unconventional medicine in children in Italy. *Eur J Pediatr* 2002;161:690.
33. Menniti-Ippolito F, Saggiocca L, Da Cas R, Saggiomo G, Di Nardo R, Traversa G. Niflumic acid and cutaneous reactions in children. *Arch Dis Child* 2001;84:430-431.
34. Traversa G, Maggini M, Menniti-Ippolito F, Bruzzi P, Chiarotti F, Greco D, Spila-Alegiani S, Raschetti R, Benagiano G, for the Italian Study Group for the Di Bella Multitherapy Trials. The Di Bella unconventional cancer treatment: a reflection on the Italian experience. *Cancer* 1999;86:1903-1911.
35. Tosti ME, Traversa G, Bianco E, Mele A. Multiple sclerosis and vaccination against hepatitis B: analysis of risk benefit profile. *Ital J Gastroenterol Hepatol* 1999;31:388-391.
36. Raschetti R, Greco D, Menniti-Ippolito F, Spila-Alegiani S, Traversa G, Benagiano G, Bruzzi P. Criticism ignores standard methodology of cancer treatment. *BMJ* 1999;318:1074. (lettera)
37. Italian Study Group for the Di Bella Multitherapy Trials. Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. *BMJ* 1999;318:224-228.
38. Menniti Ippolito F, Maggini M, Raschetti R, Da Cas R, Traversa G. reply to: Outpatient use pattern for ketorolac is distinct from comparator drugs. *Eur J Clin Pharmacol* 1999;55:83.
39. Traversa G, Spila Alegiani S, Arpino C, Ferrara M. Prescription of neuroleptics for children and adolescents in Italy. *J Child Adolescent Psychopharmacology* 1998;8:175-179.
40. Traversa G, Menniti Ippolito F, Da Cas R, Mele A, Pulsoni A. Drug use and acute leukemia. *Pharmacoepidemiology and Drug Safety* 1998;7:113-122.
41. Menniti Ippolito F, Maggini M, Raschetti R, Da Cas R, Traversa G, Walker AM. Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy. *Eur J Clin Pharmacol* 1998;54:393-397.

42. Pelosio A, Longhi C, Marchetti P, Menniti Ippolito F, Traversa G. Siesta, night sleep and blood pressure dropping. *Blood Pressure Monitoring* 1997;2:27-30.
43. Tebano MT, Traversa G, Da Cas R, Loizzo A. Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome. *Aliment Pharmacol Ther* 1996;10:659-663.
44. Maggini M, Raschetti R, Traversa G. Drug prescription in Italy. *Eur J Clin Pharmacol* 1996;49:429-430.
45. Traversa G, Walker AM, Menniti Ippolito F, Caffari B, Capurso L, Dezi A, Koch M, Maggini M, Spila Alegiani S, Raschetti R. reply to: Toxicity of different nonsteroidal antiinflammatory drugs. *Epidemiology* 1995;6:466-7.
46. Traversa G, Walker AM, Menniti Ippolito F, Caffari B, Capurso L, Dezi A, Koch M, Maggini M, Spila Alegiani S, Raschetti R. Gastroduodenal toxicity of different NSAIDs: a case-control study in the province of Rome. *Epidemiology* 1995;6:49-54.
47. Raschetti R, Maggini M, Popoli P, Caffari B, Da Cas R, Menniti Ippolito F, Spila Alegiani S, Traversa G. Gangliosides and Guillain-Barre' syndrome. *J Clin Epidemiol* 1995;48:1399-405.
48. Arpino C, Da Cas R, Donini G, Pasquini P, Raschetti R, Traversa G. Use and misuse of antidepressant drugs in a random sample of the population of Rome, Italy. *Acta Psychiatr Scand* 1995;92:7-9.
49. Cagliano S, Traversa G. The use of placebo controls. *N Engl J Med* 1995;332:60 (lettera).
50. Raschetti R, Spila Alegiani S, Diana G, Da Cas R, Traversa G, Pasquini P. Antipsychotic drug prescription in general practice in Italy. *Acta Psychiatr Scand* 1993;87:317-321.
51. Taroni F, Stiassi, Traversa G, Raschetti R, Menniti-Ippolito F, Maggini M and Spila-Alegiani S. The nature, content and interpractice variation of general practice: a regional study in Italy. *Eur J Epidemiol* 1990;6:313-318.